Search

Background: Anemia is common among ortho-geriatric hip fracture patients and is associated with prolonged recovery and increased postoperative mortality rate. Intravenous iron seems to increase hemoglobin recovery and reduce the mortality rate in patients undergoing orthopedic surgeries. This study investigated the association between short-term mortality risk and intravenous iron therapy in older patients undergoing hip fracture surgery. Methods: This observational study included 210 patients undergoing hip fracture surgery from July 2018 to May 2020. These 210 patients were alive and had a hemoglobin ≤ 6.5 mmol/L on the 3rd postoperative day. In May 2019, a local intravenous iron therapy protocol was implemented and recommended intravenous iron (Monofer©) if hemoglobin on the 3rd postoperative day was ≤ 6.5 mmol/L. According to the treatment of postoperative anemia between the 1st and 3rd day post-surgery, the patients were divided into four groups: no treatment (n=52), blood transfusion (n=38), IV Monofer (n=80), and blood transfusion and IV Monofer (n=40). Primary outcome was 30-day mortality post-surgery. The secondary outcome was the impact on hemoglobin level 14–30 days postoperatively. Multivariable Cox regression was used to estimate the 30-day mortality standardized for covariates. Results: Of 210 patients, 17 (8.1%) died within 30 days after surgery. There was a significantly lower mortality among the patients who received IV Monofer compared to those who received no treatment (HR 0.17, 95% CI [0.03–0.93], P = 0.041). Among the 86 patients with available hemoglobin measurements within 14 to 30 days post-surgery, there was no significant difference in hemoglobin level between the various treatment groups (mean 6.6 mmol/L, P = 0.1165). Conclusion: IV Monofer on the 3rd postoperative day in older hip fracture patients seemed to reduce 30-day mortality compared with no treatment. No significant differences in hemoglobin levels between 14 and 30 days post-surgery across treatment groups were found, although this was assessed in a subset of patients with available hemoglobin levels warranting further study. [ABSTRACT FROM AUTHOR]

ABSTRACT Risk of cardiovascular disease (CVD) in patients with classical Hodgkin lymphoma (cHL) undergoing contemporary treatment is unclear. cHL patients ≥ 18 years at diagnosis treated with doxorubicin‐containing chemotherapy between 2000 and 2022 were matched 1:5 with comparators on birth year, sex, and Charlson Comorbidity Index at time of matching (score of 0 or ≥ 1). Cause‐specific cumulative incidence of a composite of CVDs with corresponding 95% confidence intervals (CIs) were computed with death and lymphoma relapse as competing events (i.e., by censoring individuals at such occurrences) using the Aalen‐Johansen estimator. A total of 1905 patients and 9525 comparators with a median follow‐up of 10 years (interquartile range, [IQR]: 5.9–17.4). Median age was 39 years (IQR: 27–56), median cumulative doxorubicin dose was 250 mg/m2 (IQR: 200–300). The CVD cumulative incidences were 4.7% (95% CI: 3.6–5.7) for patients versus 2.6% (95% CI: 2.3–2.9) for comparators at 5 years, 8.9% (95% CI: 7.2–10.5) versus 5.5% (95% CI: 4.9–6.0) at 10 years, and 17.0% (95% CI: 14.1–19.9) versus 8.2% (95% CI: 7.4–9.0) at 15 years. CVD remains a substantial effect after contemporary treatment for cHL, suggesting that awareness of symptoms and a low threshold for referral to diagnostic examination are still important measures during survivorship. [ABSTRACT FROM AUTHOR]

Introduction: Patients with myocarditis have variable prognosis. Large population-based studies are required for further clarification. In this case cohort study, the aim was to determine the mortality rate among people affected by myocarditis compared to age- and sex-matched population controls. Methods: Nationwide healthcare registries were used to identify patients who were hospitalized and diagnosed with myocarditis between 1999-2015 in Denmark. Myocarditis patients were matched 1:5 to population controls, using birth year, sex and calendar month of the myocarditis event. Two-year all-cause mortality was reported using Kaplan-Meier estimates and shared Frailty Cox regression, with hazard ratios (HRs) and 95% confidence intervals (CI). Due to a steep mortality rate in the first month of follow-up, where the proportional hazards assumption was violated, we used a Split function to report HRs for after one month to two-year follow-up. Results: Of 15,532 subjects enrolled, 2,589 were diagnosed with myocarditis and 12,945 were controls. The median age was 48 in both groups. Relative to controls, myocarditis patients had higher cardiac and non-cardiac comorbidity. The crude 2-year mortality was 13.7% (95% CI 12.42-15.08) in the myocarditis group (Figure 1), compared to 3.31% (95% CI 3.00-3.61) among controls, with a crude HR of 3.23 (95% CI 2.77-3.78). The corresponding HR, adjusted for age, sex and comorbidities was 2.83 (95% CI 2.39-3.36). When excluding preexisting comorbidities, 2-year all-cause mortality was 5.6% for myocarditis patients (95% CI 4.5-6.8) vs. 1.7% for controls (95% CI 1.5-1.9). Conclusions: Patients with myocarditis have significantly higher mortality relative to age- and sex- matched population controls. Our results suggest myocarditis patients should be actively investigated and treated with plans for follow-up. Our findings suggest that the prognosis among patients with myocarditis have a poor prognosis, even when adjusted for comorbidities. The most deaths occur during the first month. [ABSTRACT FROM AUTHOR]